Satsuma Pharmaceuticals, Inc. filed its 10-K on Mar 28, 2023 for the period ending Dec 31, 2022. In this report its auditor, KPMG LLP - Klynveld Peat Marwick Goerdeler, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Satsuma Pharmaceuticals, Inc.
Equities
STSA
US80405P1075
Biotechnology & Medical Research
1st Jan change | Capi. | |
---|---|---|
+8.66% | 114B | |
+11.35% | 104B | |
-12.78% | 22.41B | |
-1.05% | 22.28B | |
-5.29% | 19.07B | |
-38.29% | 18B | |
-4.07% | 17.89B | |
+7.78% | 14.28B | |
+35.02% | 12.55B |